TH104
Search documents
Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl
Globenewswire· 2025-09-04 12:01
Core Insights - Tharimmune, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs [1][4] - The company will participate in three major Fall conferences to present new results, including the ACG Annual Scientific Meeting, AASLD Annual Conference, and AAPS PharmSci 360 [2][3] Company Overview - Tharimmune's lead clinical asset, TH104, targets respiratory and/or nervous system depression in military personnel and chemical incident responders exposed to high-potency opioids [4] - The expanded pipeline includes indications for chronic pruritus in primary biliary cholangitis and TH023, which addresses autoimmune diseases [4] - The company utilizes proprietary EpiClick Technology for a multispecific biologic platform targeting solid tumors and has a license agreement with OmniAb, Inc. for antibody discovery technology [4]
HILLSTREAM BIOPH(HILS) - Prospectus(update)
2023-11-17 21:22
As filed with the Securities and Exchange Commission on November 17, 2023 Registration Statement No. 333-275350 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER (I.R.S. Employer Identification Number) 1200 Route 22 East, Suite 2000 Bridgewater, NJ 08807 (908) 955-3140 THE SECURITIES ACT OF 1933 THARIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 2834 84-2642541 (State or other jurisdiction of incorpo ...
Tharimmune(THAR) - Prospectus(update)
2023-11-17 21:22
As filed with the Securities and Exchange Commission on November 17, 2023 Registration Statement No. 333-275350 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 THARIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 2834 84-2642541 Rob Condon, Esq. Dentons US LLP 1221 Avenue of the Americas New York, NY 10020-1089 Tel.: (212) 768-6700 Approximate date of commencement of propos ...
Tharimmune(THAR) - Prospectus
2023-11-06 22:12
As filed with the Securities and Exchange Commission on November 6, 2023 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 THARIMMUNE, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 84-2642541 (I.R.S. Employer Identification Number) 1200 Route 22 ...
HILLSTREAM BIOPH(HILS) - Prospectus
2023-11-06 22:12
As filed with the Securities and Exchange Commission on November 6, 2023 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 THARIMMUNE, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 84-2642541 (I.R.S. Employer Identification Number) 1200 Route 22 ...